New York, NYNCT04614558Now EnrollingIRB Ready

Monoclonal Gammopathy Clinical Trial in New York, NY

Access cutting-edge monoclonal gammopathy treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.

Sponsored by Columbia University

Quick Self-Assessment

See if you qualify for this New York location

Preparing your pre-screening questions...

Expert Care in New York

Access monoclonal gammopathy specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related monoclonal gammopathy treatment provided free

Apply for This New York Location

Check if you qualify for this monoclonal gammopathy clinical trial in New York, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New York

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New York site if eligible
  4. 4Begin participation

About This Monoclonal Gammopathy Study in New York

The purpose of this study is to see whether Isatuximab can help improve kidney function of participants with MGRS. Isatuximab is approved by the Food and Drug Administration (FDA) for the treatment of adult patients with multiple myeloma, but it is not approved by the FDA to treat MGRS. This means that the use of isatuximab in this study is considered 'investigational'.

Sponsor: Columbia University

Who Can Participate

Inclusion Criteria

Renal biopsy proven diagnosis of an MGRS disorder including the following: 1. Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) 2. C3 glomerulopathy associated with monoclonal gammopathy 3. Non-Amyloid Fibrillary Glomerulonephritis 4. Light chain Proximal Tubulopathy 5. Immunotactoid Glomerulopathy A concurrent diagnosis of Monoclonal gammopathy (with +ve Serum and/or Urine protein electrophoresis or Bone marrow biopsy) is required in patients with C3 glomerulopathy but not for other disorders. Patients with concurrent MGUS, non-high risk smoldering myeloma are eligible for enrollment. 2. Measurable Proteinuria ≥1gram over 24 hours. 3. Prior Therapy: Newly diagnosed as well as patients with previous therapy but persistent renal dysfunction and persistent proteinuria ≥1gram over 24 hours are eligible for enrollment. Patients who received a prior cluster of differentiation 38 (CD38) antibody therapy are not eligi

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT04614558) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Monoclonal Gammopathy Treatment Options in New York, NY

If you're searching for monoclonal gammopathy treatment options in New York, NY, this clinical trial (NCT04614558) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced monoclonal gammopathy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all monoclonal gammopathy clinical trials near you to find additional studies recruiting in your area.

More Multiple Myeloma Trials in New York, NY

See all multiple myeloma clinical trials recruiting in New York — not just this study.

Browse Multiple Myeloma Trials in New York

Ready to Join in New York?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New York, NY